Skip to main content
. 2020 Feb;6(1):a004549. doi: 10.1101/mcs.a004549

Figure 1.

Figure 1.

Areas of cerebriform lesion on soles before (A,C) and at follow-up after 12 mo treatment with miransertib 50 mg (25 mg/m2) per day (B,D), for right (A,B) and left (C,D) sole. Underneath the photographs are calculated areas of the lesion on each sole (see Methods).